Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 57

1.

Effect of induction therapy with lenalidomide, doxorubicin, and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma.

Terpos E, Katodritou E, Symeonidis A, Zagouri F, Gerofotis A, Christopoulou G, Gavriatopoulou M, Christoulas D, Ntanasis-Stathopoulos I, Kourakli A, Konstantinidou P, Kastritis E, Dimopoulos MA.

Int J Cancer. 2019 Jan 16. doi: 10.1002/ijc.32125. [Epub ahead of print]

PMID:
30650184
2.

Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.

Terpos E, Katodritou E, de la Rubia J, Hungria V, Hulin C, Roussou M, Delforge M, Bries G, Stoppa AM, Aagesen J, Sargin D, Belch A, Ahlberg L, Diels J, Olie RA, Robinson D Jr, Spencer M, Potamianou A, van de Velde H, Dimopoulos MA.

Eur J Haematol. 2018 Oct;101(4):556-565. doi: 10.1111/ejh.13147. Epub 2018 Sep 5.

PMID:
30027641
3.

Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.

Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E.

Ann Hematol. 2018 Sep;97(9):1747. doi: 10.1007/s00277-018-3404-8.

PMID:
29943159
4.

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.

Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E.

Ann Hematol. 2018 Sep;97(9):1671-1682. doi: 10.1007/s00277-018-3361-2. Epub 2018 May 13. Erratum in: Ann Hematol. 2018 Jun 26;:.

5.

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.

Katodritou E, Terpos E, Delimpasi S, Kotsopoulou M, Michalis E, Vadikolia C, Kyrtsonis MC, Symeonidis A, Giannakoulas N, Vadikolia C, Michael M, Kalpadakis C, Gougopoulou T, Prokopiou C, Kaiafa G, Christoulas D, Gavriatopoulou M, Giannopoulou E, Labropoulou V, Verrou E, Kastritis E, Konstantinidou P, Anagnostopoulos A, Dimopoulos MA.

Blood Cancer J. 2018 Mar 9;8(3):31. doi: 10.1038/s41408-018-0059-6.

6.

Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies.

Zagouri F, Kastritis E, Zomas A, Terpos E, Katodritou E, Symeonidis A, Delimpasi S, Pouli A, Vassilakopoulos TP, Michalis E, Giannouli S, Kartasis Z, Christoforidou A, Kokoviadou K, Hatzimichael E, Gika D, Megalakaki C, Papaioannou M, Kyrtsonis MC, Konstantopoulos K, Dimopoulos MA; Greek Myeloma Study Group.

Eur J Haematol. 2017 Nov;99(5):409-414. doi: 10.1111/ejh.12923. Epub 2017 Sep 26.

PMID:
28675766
7.

Is it possible to cure myeloma without allogeneic transplantation?

Katodritou E, Papadaki S, Konstantinidou P, Terpos E.

Transfus Apher Sci. 2016 Feb;54(1):63-70. doi: 10.1016/j.transci.2016.01.015. Epub 2016 Jan 21. Review.

PMID:
26850930
8.

Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience.

Katodritou E, Terpos E, Kastritis E, Delimpasis S, Symeonidis AS, Repousis P, Kyrtsonis MC, Vadikolia C, Michalis E, Polychronidou G, Michael M, Papadaki S, Papathanasiou M, Kokoviadou K, Kioumi A, Vlachaki E, Hadjiaggelidou C, Kouraklis A, Patsias I, Gavriatopoulou M, Kotsopoulou M, Verrou E, Gastari V, Christoulas D, Giannopoulou E, Pouli A, Konstantinidou P, Anagnostopoulos A, Dimopoulos MA.

Ann Hematol. 2015 Dec;94(12):2033-42. doi: 10.1007/s00277-015-2484-y. Epub 2015 Sep 30.

PMID:
26420061
9.

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.

Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Roussou M, Hadjiharissi E, Symeonidis A, Repoussis P, Michalis E, Delimpasi S, Tsatalas K, Tsirigotis P, Vassou A, Vervessou E, Katodritou E, Gika D, Terpos E, Dimopoulos MA.

Blood. 2015 Sep 10;126(11):1392-4. doi: 10.1182/blood-2015-05-647420. No abstract available.

10.

PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy.

Vassilakopoulos TP, Pangalis GA, Chatziioannou S, Papageorgiou S, Angelopoulou MK, Galani Z, Kourti G, Prassopoulos V, Leonidopoulou T, Terpos E, Dimopoulou MN, Sachanas S, Kalpadakis C, Konstantinidou P, Boutsis D, Stefanoudaki E, Kyriazopoulou L, Siakantaris MP, Kyrtsonis MC, Variami E, Kotsianidis I, Symeonidis A, Michali E, Katodritou E, Kokkini G, Tsatalas C, Papadaki H, Dimopoulos MA, Sotiropoulos V, Pappa V, Karmiris T, Meletis J, Apostolidis J, Datseris I, Panayiotidis P, Konstantopoulos K, Roussou P, Rondogianni P.

Leukemia. 2016 Jan;30(1):238-42. doi: 10.1038/leu.2015.120. Epub 2015 May 14. No abstract available.

PMID:
25971363
11.

Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.

Katodritou E, Terpos E, Symeonidis AS, Pouli A, Kelaidi C, Kyrtsonis MC, Kotsopoulou M, Delimpasi S, Christoforidou A, Giannakoulas N, Viniou NA, Stefanoudaki E, Hadjiaggelidou C, Christoulas D, Verrou E, Gastari V, Papadaki S, Polychronidou G, Papadopoulou A, Giannopoulou E, Kastritis E, Kouraklis A, Konstantinidou P, Anagnostopoulos A, Zervas K, Dimopoulos MA.

Am J Hematol. 2014 Aug;89(8):803-8. doi: 10.1002/ajh.23745. Epub 2014 May 12.

12.

Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma.

Kastritis E, Zagouri F, Symeonidis A, Roussou M, Sioni A, Pouli A, Delimpasi S, Katodritou E, Michalis E, Michael M, Hatzimichael E, Vassou A, Repousis P, Christophoridou A, Kartasis Z, Stefanoudaki E, Megalakaki C, Giannouli S, Kyrtsonis MC, Konstantopoulos K, Spyroupoulou-Vlachou M, Terpos E, Dimopoulos MA; Greek Myeloma Study Group.

Leukemia. 2014 Oct;28(10):2075-9. doi: 10.1038/leu.2014.110. Epub 2014 Mar 18.

PMID:
24637336
13.

Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents.

Zagouri F, Kastritis E, Symeonidis AS, Giannakoulas N, Katodritou E, Delimpasi S, Repousis P, Terpos E, Dimopoulos MA; Greek Myeloma Study Group.

Eur J Haematol. 2014 Apr;92(4):308-12. doi: 10.1111/ejh.12255. Epub 2014 Jan 26.

PMID:
24460646
14.

Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.

Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P, Kartasis Z, Parcharidou A, Michael M, Michalis E, Gika D, Symeonidis A, Pouli A, Konstantopoulos K, Terpos E, Kastritis E.

Ann Oncol. 2014 Jan;25(1):195-200. doi: 10.1093/annonc/mdt483.

PMID:
24356630
15.

Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.

Katodritou E, Terpos E, Kelaidi C, Kotsopoulou M, Delimpasi S, Kyrtsonis MC, Symeonidis A, Giannakoulas N, Stefanoudaki A, Christoulas D, Chatziaggelidou C, Gastari V, Spyridis N, Verrou E, Konstantinidou P, Zervas K, Dimopoulos MA.

Am J Hematol. 2014 Feb;89(2):145-50. doi: 10.1002/ajh.23600. Epub 2013 Nov 21.

16.

The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group.

Terpos E, Christoulas D, Kastritis E, Katodritou E, Papatheodorou A, Pouli A, Kyrtsonis MC, Michalis E, Papanikolaou X, Gkotzamanidou M, Koulieris E, Gavriatopoulou M, Zervas K, Dimopoulos MA; Greek Myeloma Study Group.

Am J Hematol. 2014 Jan;89(1):34-40.

17.

"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.

Katodritou E, Vadikolia C, Lalagianni C, Kotsopoulou M, Papageorgiou G, Kyrtsonis MC, Matsouka P, Giannakoulas N, Kyriakou D, Karras G, Anagnostopoulos N, Michali E, Briasoulis E, Hatzimichael E, Spanoudakis E, Zikos P, Tsakiridou A, Tsionos K, Anargyrou K, Symeonidis A, Maniatis A, Terpos E.

Ann Hematol. 2014 Jan;93(1):129-39. doi: 10.1007/s00277-013-1841-y. Epub 2013 Jul 28.

PMID:
23892921
18.

The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations?

Terpos E, Christoulas D, Kastritis E, Katodritou E, Pouli A, Michalis E, Papassotiriou I, Dimopoulos MA; Greek Myeloma Study Group.

Eur J Haematol. 2013 Oct;91(4):347-55. doi: 10.1111/ejh.12164. Epub 2013 Aug 17.

PMID:
23829647
19.

Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era.

Dimopoulos MA, Kastritis E, Delimpasi S, Katodritou E, Hatzimichael E, Kyrtsonis MC, Repousis P, Tsirogianni M, Kartasis Z, Parcharidou A, Michael M, Michalis E, Tsatalas C, Stefanoudaki E, Hatjiharissi E, Gika D, Symeonidis A, Terpos E, Zervas K; Greek Myeloma Study Group.

Eur J Haematol. 2012 Jul;89(1):10-5. doi: 10.1111/j.1600-0609.2012.01784.x.

PMID:
22469521
20.

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.

Terpos E, Christoulas D, Katodritou E, Bratengeier C, Gkotzamanidou M, Michalis E, Delimpasi S, Pouli A, Meletis J, Kastritis E, Zervas K, Dimopoulos MA.

Int J Cancer. 2012 Sep 15;131(6):1466-71. doi: 10.1002/ijc.27342. Epub 2011 Dec 21.

Supplemental Content

Loading ...
Support Center